Cancer Chemotherapy and Pharmacology

Article	Citations
Tumor microenvironment promotes breast cancer chemoresistance	155
Disulfiram: a novel repurposed drug for cancer therapy	85
Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells	71
Artemisinin-type drugs for the treatment of hematological malignancies	41
The role of the glutamine transporter ASCT2 in antineoplastic therapy	30
Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway	25
Long non-coding RNAs: controversial roles in drug resistance of solid tumors mediated by autophagy	23
Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway	22
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer	22
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)	22
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases	21
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach	21
EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer	21
Panobinostat penetrates the blood–brain barrier and achieves effective brain concentrations in a murine model	19
Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2/M cell cycle arrest, apoptosis, and autophagy	19
FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway	18
Translational model of melphalan-induced gut toxicity reveals drug-host-microbe interactions that drive tissue injury and fever	18
Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance	18
Human placental extract ameliorates methotrexate-induced hepatotoxicity in rats via regulating antioxidative and anti-inflammatory responses	18
Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment	17
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies	17
Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors	17
Time-dependent population PK models of single-agent atezolizumab in patients with cancer	16
Evaluation of drug–drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)	15
Disulfiram/copper induces antitumor activity against gastric cancer cells in vitro and in vivo by inhibiting S6K1 and c-Myc	15

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology	15
MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism	15
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study	15
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types	15
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma	15
Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function	14
Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition	14
Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma	14
PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1	14
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial	14
Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients	13
Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis	13
Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer	13
A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors	13
Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype	13
Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota	13
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer	13
A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects	13
Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma	12
Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review	12
Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas	12
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers	12
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients	12
Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours	12
Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients	11
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants	11
Use of cucurbitacins for lung cancer research and therapy	11
Targeting cPLA2α inhibits gastric cancer and augments chemotherapy efficacy via suppressing Ras/MEK/ERK and Akt/β-catenin pathways	11
The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study	11
The use of vitamin E in preventing taxane-induced peripheral neuropathy	11
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment	11
Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation	11
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach	11
Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma	11
5-Fluorouracil disrupts ovarian preantral follicles in young C57BL6J mice	11
Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics	11
Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate	11
Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer	11
Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis	11
An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next	10
ATF4-mediated microRNA-145/HDAC4/p53 axis affects resistance of colorectal cancer cells to 5-fluorouracil by regulating autophagy	10
Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation	10
Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma	10
Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers	10
A systematic review of inter-individual differences in the DNA repair processes involved in melphalan monoadduct repair in relation to treatment outcomes	10
Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results	10
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells	10
Demethoxycucumin protects MDA-MB-231 cells induced bone destruction through JNK and ERK pathways inhibition	9
MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma	9
Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma	9

Zileuton inhibits arachidonate-5-lipoxygenase to exert antitumor effects in preclinical cervical cancer models	9
Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1	9
Anticancer potential of metformin: focusing on gastrointestinal cancers	9
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment	9
Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients	9
Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1–XPF-mediated DNA repair	9
The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update	9
Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1–NRF2 signaling	9
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer	9
Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin	9
A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy	9
Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway	9
Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors	9
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors	8
Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway	8
Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis	8
Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors	8
Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models	8
Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression	8
Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer	8
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl	8
Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies	8
Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population	8
Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine	8
Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study	8
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer	8
Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations	7
Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement	7
Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole	7
An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib	7
Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs	7
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants	7
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies	7
Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission	7
Prediction of drug–drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling	7
Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2	7
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment	7
A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors	7
Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice—a prospective single-center trial	7
A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers	7
A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors	7
Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies	7
Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma	7
The use of zebrafish model in prostate cancer therapeutic development and discovery	7
Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy	7
Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling	7
Hsp90 inhibition sensitizes DLBCL cells to cisplatin	7
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma	7
The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia	7
Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study	7
Cardiovascular toxicity of breast cancer treatment: an update	7
Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2– advanced breast cancer in Chinese women	7
Population pharmacokinetic model development and exposure–response analysis of vincristine in patients with malignant lymphoma	6
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure	6
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors	6
Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways	6
Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer	6
Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer	6
A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese ma	6
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies	6
The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent	6
Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic–pharmacodynamic real-life study	6
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer	6
Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants	6
A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarco	6
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast	6
A phase I study of the ceramide nanoliposome in patients with advanced solid tumors	6
Anti-drug antibodies in the current management of cancer	6
Upregulation of TRIB2 by Wnt/β-catenin activation in BRAFV600E papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib	6
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast canc	6
Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase	6
An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16	6
The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 st	6
Mechanism of cisplatin resistance in gastric cancer and associated microRNAs	6
Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma	6
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma	6
Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors	6
Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia	6
Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia	6
Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis	6

Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case–control study	6
RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment	6
Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children’s Oncology Group Study ADVL06B1	6
FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study	6
BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series	6
Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug–drug interactions with oral targeted therapy	5
Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens	5
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients	5
Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model	5
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients	5
Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics	5
Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment	5
Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon	5
Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers	5
Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas	5
Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors	5
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib	5
Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach	5
Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors	5
Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane	5
Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice	5
Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma	5
Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive bio	5
Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities	5
Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer	5
Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients	5
Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury	5
Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib	5
Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study	5
SOX8 promotes cetuximab resistance via HGF/MET bypass pathway activation in colorectal cancer	5
Efficacy and safety exposure–response analyses of entrectinib in patients with advanced or metastatic solid tumors	4
Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer	4
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients	4
Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib	4
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations	4
Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients	4
Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer	4
Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review	4
Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies	4
A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis	4
A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma	4
Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy	4
Glaucocalyxin A induces apoptosis and autophagy in tongue squamous cell carcinoma cells by regulating ROS	4
Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis	4
Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor	4
Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients	4
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma	4
NCTR25 fusion facilitates the formation of TRAIL polymers that selectively activate TRAIL receptors with higher potency and efficacy than TRAIL	4
Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia	4
No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study	4
Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors	4
Minimal PK/PD model for simultaneous description of the maximal tolerated dose and metronomic treatment outcomes in mouse tumor models	4
A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects	4
A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis	4
Correlation between pharmacokinetic parameters of 5-fluorouracil and related metabolites and adverse reactions in East-Asian patients with advanced colorectal cancer	4
Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease	4
A prospective feasibility study of uracil–tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study	4
A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C	4
Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults	4
Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation	4
Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer	3
Detecting DPD deficiency: when perfect is the enemy of good	3
Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability	3
Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review	3
A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and bil	3
Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab	3
Phase I study of tamibarotene monotherapy in pediatric and young adult patients with recurrent/refractory solid tumors	3
A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies	3
Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients	3
Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report	3
4-(N)-Docosahexaenoyl 2’, 2’-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent	3
Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms	3
Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer	3
Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells	3
Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice	3
Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma	3
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship	3
Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model‐based population pharmacokinetic analysis	3
Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model	3
Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients	3
The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo	3
Optimized scaling of translational factors in oncology: from xenografts to RECIST	3
PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials	3
A minimal physiologically based pharmacokinetic model for high-dose methotrexate	3
Megestrol acetate is a specific inducer of CYP3A4 mediated by human pregnane X receptor	3
Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations	3
Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review	3
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors	3
Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management	3
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors	3
Cardioprotective potential of mitochondria-targeted antioxidant, mito-TEMPO, in 5-fluorouracil-induced cardiotoxicity	3
Dynamics of leucocyte DNA thioguanine nucleotide levels during maintenance therapy of childhood acute lymphoblastic leukemia	3
Comparison of a thymine challenge test and endogenous uracil–dihydrouracil levels for assessment of fluoropyrimidine toxicity risk	3
Pharmacology and pharmacokinetics of elacestrant	3
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats	3